Ironwood pharmaceutical company submits the new drug application for iw2143 to FDA
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ironwood pharmaceutical company submits the application for new drug iw-2143 (ind) to the US Food and Drug Administration (FDA) for clinical research Clinical studies will further evaluate the pharmacokinetics of the antianxiety drug in healthy volunteers "We have a strong R & D team in Ironwood and have designed a complete set of clinical research programs for iw-2143," said Deborah, CEO and head of management of Ironwood Pre clinical studies have shown that iw-2143 has a significant anti anxiety effect and can stimulate neurite growth.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
